Accumulation of Dietary S-Methyl Cysteine Sulfoxide in Human Prostate Tissue by Coode-Bate, Jack et al.
RESEARCH ARTICLE
Cruciferous Vegetables www.mnf-journal.com
Accumulation of Dietary S-Methyl Cysteine Sulfoxide in
Human Prostate Tissue
Jack Coode-Bate, Tharsini Sivapalan, Antonietta Melchini, Shikha Saha, Paul W. Needs,
Jack R. Dainty, Jean-Bapiste Maicha, Gemma Beasy, Maria H. Traka, Robert D. Mills,
Richard Y. Ball, and Richard F. Mithen*
Scope: Observational studies have associated consumption of cruciferous
vegetables with reduced risk of prostate cancer. This eﬀect has been
associated with the degradation products of glucosinolates—thioglycosides
that accumulate within crucifers. The possible role of S-methyl cysteine
sulfoxide, a metabolite that also accumulates in cruciferous vegetables, and
its derivatives, in cancer prevention is relatively unexplored compared to
glucosinolate derivatives. The hypothesis that consuming a broccoli soup
results in the accumulation of sulfate (a SMCSO derivative) and other
broccoli-derived metabolites in prostate tissue is tested.
Methods and results: Eighteen men scheduled for transperineal prostate
biopsy were recruited into a 4-week parallel single blinded diet
supplementation study (NCT02821728). Nine men supplemented their diet
with three 300 mL portions of a broccoli soup each week for four weeks prior
to surgery. Analyses of prostate biopsy tissues reveal no detectable levels of
glucosinolates and derivatives. In contrast, SMCSO is detected in prostate
tissues of the participants, with signiﬁcantly higher levels in tissue of men in
the supplementation arm. SMCSO was also found in blood and urine samples
from a previous intervention study with the identical broccoli soup.
Conclusion: The consequences of SMCSO accumulation in prostate tissues
and its potential role in prevention of prostate cancer remains to be
investigated.
1. Introduction
Epidemiological studies have suggested an association between
consumption of cruciferous vegetables and prevention of inci-
dence or progression of prostate cancer.[1–4] The strength of the
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association varies greatly between stud-
ies, with some studies suggesting con-
sumption of four portions of crucifer-
ous vegetables per week can reduce risk
of progression from low-grade organ-
conﬁned cancer to advanced disease by
up to 60%,[1] while other studies have
found no association.[5]
Cruciferous vegetables accumulate
glucosinolates, sulfur-containing glyco-
sides that are hydrolyzed by either plant
or microbial-derived thioglucosidases to
generate an array of biologically active
compounds including isothiocyanates
and indoles (Figure 1a,b).[6] The bio-
logical activities of these derivatives as
demonstrated in cell and animal models
are widely considered to underpin the
protective eﬀects of these vegetables
in the human diet.[7] In addition to
glucosinolates, cruciferous vegetables ac-
cumulate (+)-S-methyl cysteine sulfoxide
(SMCSO or methiin),[8,9] often to signif-
icantly higher concentrations (1–4% dry
weight) than that of glucosinolates (0.1–
0.6%).[10,11] SMCSO is degraded by plant
or microbial cysteine conjugate 𝛽 lyases
to generate a range of biologically active
metabolites, including methanic acid, S-methyl methanethiosul-
fonate, S-methyl methanethiosulﬁnate, dimethyl disulphide, and
dimethyl trisulﬁde (Figure 1c).[11,12] Some of these products have
been shown to inhibit chemically induced carcinogenesis when
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Figure 1. a) 4-Methylsulphinylbutyl glucosinolate (glucoraphanin) and its hydrolysis to the corresponding isothiocyanate, sulforaphane. b) S-
methylcysteine sulfoxide (SMCSO,methiin) and its degradation products. 𝛽-eliminative enzymatic cleavage of SMCSOproduces highly reactivemethane-
sulfenic acid (equation (1)). Spontaneous nucleophilic attack of one molecule of methanesulfenic acid on another leads to the formation of S-methyl
methanethiosulﬁnate (IUPAC name methylsulﬁnylsulfanylmethane*, equation (2)). This can disproportionate (equation (3)) to form dimethyl disulﬁde
and S-methyl methanethiosulfonate (MMTS, IUPAC name methylsulfonylsulfanylmethane*). Nucleophilic attack of hydrogen sulﬁde (a known product
of Brassica breakdown, though its genesis is unclear) on S-methyl methanethiosulﬁnate gives disulfanylmethane, which can react in similar fashion with
a second molecule of S-methyl methanethiosulﬁnate to give dimethyl trisulﬁde (equation (4)). *Several, often inconsistent names and abbreviations
have been used for these compounds.
fed to rodents,[13–16] in a similar manner to that of freeze dried
Brassica.[17] The full pathway of SMCSO metabolism in humans,
probably initiated by the gut microbiota, remains to be eluci-
dated. It has, however, been shown that inorganic sulfate is a ma-
jor SMCSO-derivative in urine.[18]
Despite the reported biological activity of crucifer-derived
metabolites inmodel systems, it remains challenging to provide a
satisfactorymechanistic explanation of how consuming relatively
few portions of cruciferous vegetables per week can lead to a re-
duction in risk of aggressive prostate cancer. Several pharmacoki-
netic studies have shown that the concentration of glucosinolates
and isothiocyanates such as sulforaphane in plasma following a
portion of cruciferous vegetables is transient, and signiﬁcantly
lower (Cmax < 1 µm) than that frequently used in model systems
(typical exposure of 5–20 µm for 24 h).[19,20] One explanation may
be that there is accumulation of the plant-derived compounds
and/or their biological-active derivatives in prostate tissue, as has
been shown for lycopene derived from tomatoes,[21] resulting in
localized exposure of tissue to suﬃciently high concentrations to
induce changes that may result in reduction in carcinogenesis
and growth of cancerous clones.
In this study, we investigate whether consuming a broc-
coli soup rich in 4-methylsulphinybutyl glucosinolate (“gluco-
raphanin”), the precursor of the isothiocyanate sulforaphane, and
SMCSO can result in the accumulation of sulfate, the reported
major derivative from SMCSO,[18] and other broccoli-derived
metabolites in human prostate tissue. As we unexpectedly found
un-metabolized SMCSO in prostate and adipose tissues, we
additionally quantiﬁed SMCSO in tissue samples from prostate
from men who had not been involved in a dietary study, and
report the level of SMSCO in plasma and urine of volunteers
over a 24 h period following consumption of a single portion of
Mol. Nutr. Food Res. 2019, 1900461 1900461 (2 of 10) © 2019 The Authors. Published by WILEY-VCH Verlag GmbH & Co. KGaA, Weinheim
www.advancedsciencenews.com www.mnf-journal.com
Figure 2. Flow chart of pathways to recruitment.
the broccoli soup as part of a previously described dietary inter-
vention study[19] to provide further insight to the bioavailability
and metabolism of SMCSO.
2. Experimental Section
2.1. SAP Study Design
The SAP study (Figure 2) was a two-arm, parallel un-blinded,
dietary-supplementation study, delivering a short, high-dose
broccoli soup supplement to a habitual diet to men in the pre-
biopsy window before a trans-perineal prostate biopsy (TPB). The
primary aim was to determine whether supplementation of a
diet with a broccoli soup would enhance the levels of sulfate and
other broccoli-derived metabolites in the prostate of men sched-
uled for prostate biopsy. Eighteen men were randomized to ei-
ther continue their normal diet (non-supplementation controls)
or receive three portions of a glucoraphanin-rich broccoli soup
(300 g) per week for a minimum of 4 weeks manufactured from
a broccoli cultivar heterozygous for a Myb28villosa allele, as pre-
viously described.[19] On the study day, samples of whole blood,
urine (following a digital rectal prostatic massage), prostate, and
peri-prostatic adipose tissue were collected. The protocol was ap-
proved by the Human Research Governance Committee (HRGC
IFR 01/2016) at Quadram Institute Bioscience and given full eth-
ical approval by The East of England – Cambridge East Research
Ethics Committee (ref: 16/EE/0054). The trial was registered on
a publicly accessible database (ClinicalTrials.gov, NCT02821728).
The sample size for the SAP study was calculated based upon
unpublished data of presence of sulfate within biopsy tissue of
men consuming broccoli in which men randomized to a 12-
month broccoli intervention had shown a signiﬁcant accumu-
Figure 3. The eﬀect of heating soup to boiling on amount of a) gluco-
raphanin and b) SMCSO compared to unheated control by microwave or
conduction heating. Columns are means of two independent samples.
lation of sulfate in prostate tissue after the intervention period
compared to baseline. To detect a diﬀerence of 1.735 (arbitrary
units) at a 5% signiﬁcance level with 90% power and assuming
a within-group SD of 1.056 required a sample size of nine indi-
viduals in each group (total 18). These sample sizes were calcu-
lated for a two-group study design (broccoli supplementation vs
no supplementation) assuming a two-sided comparison (i.e., to
detect a diﬀerence rather than a higher level).
2.2. Dosage Information
One portion of soup contained 280 ± 8.8 µmoles of gluco-
raphanin and 1513 ± 36.8 µmoles of SMCSO. The soup was pro-
vided frozen and heated up prior to consumption using a stan-
dard procedure. Heating either by microwave or conduction had
no eﬀect on SMCSO or glucoraphanin concentration (Figure 3).
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2.3. Study Population
Menwhowere on the waiting list for TPB at Norfolk andNorwich
University Hospital as part of their routine clinical care were
targeted for enrolment if they were between the ages of 18 and 80
years and had a body mass index of between 19.5 and 35 kg m–2.
The inclusion criteria included those with either a previous neg-
ative TRUS-guided prostate biopsy or those with a histologically
conﬁrmed abnormality, including diagnosis of prostate cancer
that required further investigation or surveillance. Exclusion cri-
teria included those taking 5𝛼 reductase inhibitors, testosterone
replacement medicines, warfarin, and dietary supplements,
and those with a diagnosis of diabetes. Eligible patients were
provided with an information pack concerning the rationale for
the study and details of the supplementation. Those who wished
to take part were given a 3-day period of reﬂection before pro-
viding formal written consent. Randomization was performed
by a third party with use of an online randomization generator
(www.randomization.com).
2.4. Study Day Procedure
A sample of whole blood for genotyping was obtained via the in-
travenous cannula inserted for use by the anesthetist, thus avoid-
ing additional venipuncture. After prostatic massage, a ﬁrst-pass
urine sample was collected. TPBwas performed under general or
spinal anesthesia with appropriate antibiotic prophylaxis. Once
anesthetized, the patient was positioned supine with their legs
elevated in stirrups. A template grid was placed on the skin of the
perineum and the prostate visualized by trans-rectal ultrasound
scan. Aftermeasuring the volume of the prostate, thewhole gland
was systematically sampled through the template grid, which had
holes spaced at 5 mm intervals. For the SAP study, eight biopsy
cores of prostate tissue were taken from a region of the prostate
not known or suspected to contain cancer. Five of these were
snap frozen for metabolite analyses, two in RNAlater, and one
in methanol. Two additional cores were taken from peri-prostatic
adipose tissue and snap frozen.
2.5. Cruciferous Vegetable Food Frequency Questionnaire
To evaluate the habitual intake of cruciferous vegetables of all vol-
unteers, a cruciferous vegetable food frequency questionnaire de-
veloped and validated by the University of Arizona[22] was com-
pleted during the study day.
2.6. Sulfate and SMCSO Extraction from Prostate Tissue
Snap-frozen tissue cores were individually weighed on a high-
sensitivity balance and transferred to screw-top tubes. Two
hundred microliters of cold Milli- Q® water and 300 µg of
autoclaved, acid-washed 710 to 1180 µm glass beads were added
to each tube. The tissue was completely homogenized using a
DNA Fast-Prep® (MP Biomedicals) at 4.0 m s–1 for three cycles
of 60 s each. The samples were then placed on a revolving shaker
for 15 min at 4o C. The tubes were centrifuged at 17 000 × g for
10 min at 4 oC and 50 µL of supernatant transferred to a new
Eppendorf. 10 µL of 50% trichloroacetic acid (TCA) were added
to each sample to precipitate proteins. The centrifugation step
was repeated and 50 µL of supernatant transferred to HPLC
insert vials for analysis by LC–MS/MS.
2.7. Sulfate and SMCSO Extraction from Urine
Aliquots of urine were thawed on ice, vortexed brieﬂy and 100 µL
transferred to an Eppendorf tube. A tenfold dilution in 5% TCA
was performed, the sample vortexed and incubated on ice for
10 min to precipitate proteins. The sample was centrifuged at
14 000 × g for 10 min at 4 oC and the supernatant transferred to
an HPLC vial for analysis by LC–MS/MS.
2.8. Quantiﬁcation of Sulfate and SMCSO by LC–MS/MS
Stock solutions of 1 mg mL–1 sulfate (Sigma) and SMCSO (LKT
laboratories Inc.) were generated by dilution of weighed pow-
der into Milli-Q water. Serial ﬁvefold dilutions were performed
in the relevant matrix to produce 6-point calibration curves from
10 to 0 µg mL–1 on the day of analysis. Sulfate was quantiﬁed
using an Agilent 6490 triple-quad LC–MS mass spectrometer
(Agilent technologies) with Thermo ScientiﬁcHypercarb, Porous
Graphitic Carbon (PGC) (3 × 50 mm, 3 µm) column. Two mi-
croliters were injected from each sample, with separation by 1%
formic acid in Milli-Q water (mobile phase A) and 1% formic
acid in methanol (mobile phase B). The gradient started at 8%
mobile phase B, increasing to 70% over 5.5 min and returned to
8%mobile phase B for re-equilibration over the last 9.5 min. The
column temperature was maintained at 60 °C and the ﬂow rate at
0.3mLmin–1. The LC eluent ﬂowwas sprayed into themass spec-
trometer interface without splitting. Inorganic sulfate was mon-
itored using MS in MRM mode (m/z = 97/80 transition) with
ESI in the negative polarity. The MS source parameters were: gas
temperature 200 °C, gas ﬂow 16 L min–1, sheath gas temperature
400 °C, sheath gas ﬂow 12 L min–1, capillary voltage 3000 V and
nozzle voltage 1000 V. Quantiﬁcation of sulfate was performed by
peak area against the matrix-matched standard curve, and iden-
tiﬁcation by retention time and product ions.
SMCSO was quantiﬁed with the Agilent system described
above. Samples were injected at 2 µL eluted at a ﬂow rate of
0.3 mL min–1 on an Agilent SB-AQ 1.8 µm (100 × 21 mm) C18
column. Separation was carried out using 10 mm ammonium
acetate + 0.05% hetaﬂuorobutyric acid in Milli-Q water (mobile
phase A) and 10 mm ammonium acetate + 0.05% hetaﬂuo-
robutyric acid in 90% methanol (mobile phase B). The gradient
started at 2% mobile phase B, increasing over 2 min to 5% B
and returning to 2%mobile phase B for re-equilibration over the
last 2 min. The column was set at 20 °C due to the instability of
SMCSO at high temperatures. The LC eluent ﬂow was sprayed
into the mass spectrometer interface without splitting. SMCSO
ion was monitored by MS inMRMmode (m/z = 87.9) in positive
polarity with ESI. The source parameters were: gas temperature
200 °C, gas ﬂow 16 L min–1, sheath gas temperature 300 °C
with a sheath gas ﬂow of 11 L min–1, a nebulizer pressure of 50
psi, and capillary voltage 3500 V. Quantiﬁcation was performed
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by peak area against the matrix-matched standard curve, and
identiﬁcation by retention time and product ions.
2.9. Glucoraphanin and Glucoerucin Extraction from Tissue and
UPLC–MS/MS Analysis
Snap-frozen tissue cores were individually weighed on a high-
sensitivity balance and transferred to screw-top tubes. Two hun-
dred microliters of cold Milli-Q water and 300 µg of autoclaved,
acid-washed 710 to 1180 µm glass beads (Sigma) were added
to each tube. The tissue was completely homogenized using a
DNA Fast-Prep (MP Biomedicals) at 4.0 m s–1 for three cycles of
60 s each. The samples were then placed on a revolving shaker
for 15 min at 4 oC. The tubes were centrifuged at 17 000 × g
for 10 min at 4 oC and 50 µL of supernatant transferred to a
newEppendorf. Tenmicroliters of 50% trichloroacetic acid (TCA)
were added to each sample to precipitate proteins. The centrifu-
gation step was repeated and 50 µL of supernatant transferred
to HPLC insert vials for analysis by UPLC–MS/MS. GR and GE
were separated with 0.2% formic acid in water (mobile phase
A) and 0.2% formic acid in acetonitrile (mobile phase B) using
a Kinetex 1.7 µm XB-C18 100 Å 100 × 2.1 mm UPLC column.
The gradient started at 5%mobile phase B increasing over 7 min
to 80% mobile phase B and ﬁnally re-equilibrated to 5% mobile
phase B for 2 min. The LC eluent ﬂow was sprayed into the mass
spectrometer interface without splitting. GR ion andGE ion were
monitored using MS in MRM mode (GR 436/97; GE 412/97) in
negative polarity with ESI.
2.10. Analyses of Glucoraphanin, Sulforaphane, and
Sulforaphane Conjugates by LC–MS/MS
The analyses of sulforaphane and sulforaphane conjugates in
prostate tissue, plasma, and urine was as previously described.[19]
2.11. Analyses of SMCSO from Prostatectomy Tissue Samples
To further explore the presence of un-metabolized SMCSO in
the prostate gland of men who had not been within a dietary
study, tissue samples were obtained from patients who had
endoscopic extraperitoneal radical prostatectomies. Access to
tissue and subsequent analyses were undertaken under ethical
approval granted from the Faculty of Medicine and Health
Sciences Research Ethics Committee of the University of East
Anglia (FMHS 20122014–37). The prostate gland was removed
from the abdominal cavity immediately after resection and
rapidly biopsied after extraction to avoid ischemic artifacts using
a standard core biopsy instrument, as previously described.[23]
The extracted whole prostatectomy specimen was placed on a
surgical table, the apex and base of the gland were identiﬁed,
and the prostate cut transversely (axial section) half way along
the gland. With the use of the midline and the urethra as guides,
biopsies were taken from the peripheral zones avoiding obvious
tumor sites where feasible. Two cores were taken from each
of four glands for analyses. The tissue was snap frozen and
analyzed for the presence of SMCSO as described above.
2.12. Bioavailability and Excretion of SMCSO
To quantify the amount of SMCSO in plasma and urine from a
single portion of soup, samples were analyzed from a previously
described acute intervention study (NCT02300324).[24] In this
study, ten volunteers consumed a single portion of the identical
soup to that used in the SAP study as described above as part
of a three-phase cross-over study. Brieﬂy, men and woman
aged 18–65 years with a BMI between 19.5 and 35 kg m–2
were enrolled into a dietary intervention trial undertaken at the
Human Nutrition Unit of the Quadram Institute Bioscience
Subjects were recruited on the basis of fasted (≥8 h) screening
blood/urine samples and a completed health questionnaire. The
study involved a 48-h pre-intervention diet restriction, a study
day involving a 9-h stay at the HNU and a sample collection the
following morning (24 h post soup consumption) followed by a
washout period of 2 weeks. Participants (n = 10) were required to
follow a glucosinolate-free diet as well as avoiding alcohol, spicy
food and Allium for 48 h prior to each study day until the collec-
tion of the 24-h sample for each phase. This dietary restriction
was required to ensure that glucosinolates and SMCSO from
other food sources did not have an impact on the study results.
During each study day, eleven blood samples (10 mL) were
collected after the consumption of the soups at the following
timepoints: 0, 30, 45, 60, 90, 120, 180, 240, 360, and 480 min,
and 24 h. Six urine samples were collected at the following time-
points: 0, 0–2, 2–4, 4–6, 6–8, and 8–24 h. Ethical approval was
obtained from the Human Research Governance Committee at
QIB(IFR06/2014) and the National Research Ethics Service East
of England Norfolk Ethics Committee (reference 14/EE/1121).
The study was registered on clinictrials.gov (NCT02300324).
2.13. SMCSO and Glucosinolates in Cruciferous and Alliaceous
Vegetables
SMCSO and glucosinolates was quantiﬁed in a selection of cru-
ciferous and alliaceous vegetables purchased from a retail outlet
to provide an indication of the relative amounts of these metabo-
lites that occur in these vegetables.
2.14. Data Availability
The datasets generated and analyzed during the current study are
available from the corresponding author upon request.
3. Results
3.1. Recruitment
Ninety-two information packs were sent to patients on the
waiting list for TPB, 24 potential participants returned response
letters, and a further 27 were contacted by telephone. The con-
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Table 1. Participants. There are no diﬀerences between the two arms of the
study.
Control Supplementation
Age years 64.7 ± 5.39a) 68.6 ± 6.46
BMI [kg m–2] 26.8 ± 3.29 28.1 ± 2.58
PSA [ng ml–1] 7.8 ± 4.17 8.7 ± 2.64
PSA density [ng mL cm–3] 0.14 ± 0.101 0.12 ± 0.05
a)Mean ± SD.
version rate to full participation was high (62.5%) amongst those
who returned the response slip, primarily limited by a scheduled
biopsy date that was too soon for the supplementation. Those
that were ﬁrst contacted by telephone were less likely to meet
the inclusion criteria and only three (11%) subsequently decided
to enrol on the study. One volunteer in the non-supplementation
arm dropped out from further participation due to illness on the
study day (Figure 2).
3.2. Participant Demographics
Block randomization distributed participants equally to both
study arms, with no statistically signiﬁcant diﬀerence (unpaired
t-test) in age, BMI, prostate speciﬁc antigen (PSA), or PSA den-
sity (Table 1). The mean BMI for men in both arms fell into the
overweight category, and as anticipated formen recommended to
undergo TPB the PSA in both groups was above the age-adjusted
normal range.
3.3. Participant Cancer Grade and Volume
Despite clinical suspicion of prostate cancer indicating the need
for TPB, histology reports revealed 11 of the 18 participants had
benign diagnoses. There were no signiﬁcant diﬀerences in the
overall distribution of cancer diagnoses between the two groups.
Study biopsies were taken from the right anterior quadrant of
the prostate or the most remote region from any focal areas of
clinical suspicion. Three volunteers were diagnosed with cancer
in the quadrant sampled (two in the supplementation group and
one in the non-supplementation group). However, the volume of
tissue aﬀected was small (<15%).
3.4. Cruciferous Vegetable Intake
One volunteer failed to fully complete and return the Ari-
zona cruciferous vegetable food frequency questionnaire. As
part of their habitual diet, the supplementation group and
non-supplementation group consumed similar quantity of
cruciferous vegetables per day (67 ± 52.9 g and 72 ± 54.5 g,
respectively).
Figure 4. a) SMCSO in prostate and b) SMCSO in peri-prostatic tissue in
control and supplement groups. p-Values are from Student’s t-tests.
Figure 5. SMCSO is prostate and urine.
3.5. Dietary Supplementation Resulted in Accumulation of
SMCSO in Prostate Tissue
Higher levels of SMCSO were found in prostate tissue samples
following the broccoli supplementation compared to the non-
supplementation arm (Figure 4a). SMCSO was also detected in
peri-prostatic adipose tissues at higher levels than in prostate tis-
sue but without signiﬁcant diﬀerence between the two groups
(Figure 4b). SMCSO was higher in urine in the supplement
group compared to the control (p = 0.004, Student’s t-test) and
correlated with the levels in prostate (Figure 5, r2 = 0.52, p =
0.0007, linear regression). There was no signiﬁcant diﬀerence in
the level of sulfate in prostate tissue between the two dietary arms
(Figure 6a), and there was no correlation between prostate sulfate
and prostate SMCSO (p = 0.29, linear regression).
No glucoraphanin or sulforaphane (and its thiol conjugates)
was detected in prostate tissue. Sulforaphane was detected in
urine from participants in both arms of the study (Figure 6b).
As would be expected, levels of sulforaphane were lower in men
in the control arm who were not provided with the broccoli soup.
Two men in this arm had relatively high levels of sulforaphane
and this was a result of the consumption of broccoli within the
previous 24 h, as evident through the Arizona cruciferous veg-
etable food frequency questionnaire.
3.6. SMCSO is Present in Tissue from Radical Prostatectomies
of Men Who Had Not Been Associated with Dietary Studies
SMCSO was detected in seven of the eight tissue samples ob-
tained from radical prostatectomies (Figure 7). Levels in patient
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Figure 6. a) Sulfate in prostate tissue of control and supplement groups. b) Sulforaphane in urine of control and supplement groups. p-Values are from
Student’s t-tests.
Figure 7. SMCSO in two cores from four patients who had undergone
radical prostatectomies.
four exceeded those that occurred within the supplementation
study.
3.7. SMCSO is Found in Plasma Following Consumption of
Broccoli Soup
When samples from a previous dietary intervention study were
analyzed, SMCSO was detected in plasma and urine from sam-
ples collected at intervals within 24 h following consumption of
a single portion of the same broccoli soup as in the SAP study
(Figure 8). Peak plasma concentration occurred after 1.4 h and
peaked at 198 µmol L−1. After 24 h, 6% of consumed SMCSO
has been excreted in urine (Table 2).
3.8. SMCSO and Glucosinolates in Cruciferous and Alliaceous
Vegetables
A preliminary survey of SMCSO in cruciferous and alliaceous
vegetables indicated that SMCSO occurs at higher concentra-
tions than glucosinolates in all Brassica vegetables, but is low in
rocket (Diplotaxis tenufolia) and watercress (Nasturtium oﬃcinale;
Figure 9a). Furthermore, SMCSO occurs at higher concentra-
tions in broccoli than in leek, garlic, and onion (Figure 9b).
4. Discussion
Diets rich in cruciferous vegetables have been associated with
reduced risk of cancer at several sites, including prostate,[1,2]
breast,[25] lung,[26,27] and colon,[28] and with reduce risk of cardio-
vascular disease and atherosclerosis.[29–31] It is widely assumed
that these protective eﬀects are at least partially mediated by
glucosinolate degradation products. Indeed, a study recently
demonstrated that consuming a high-glucoraphanin broccoli
weekly for 1 year can successfully suppress transcription of
predominantly oncogenic pathways in prostate tissue of men
with localized prostate cancer.[32] However, the possible con-
tribution of SMCSO and its derivatives have received scarce
attention. In this study, we report that consuming three por-
tions of a glucoraphanin-rich soup per week for 4 weeks did
not result in accumulation of glucoraphanin or sulforaphane
in prostate tissue. Sulforaphane was detected in the urine of
volunteers in both the control and supplementation arms of
the study (Figure 7). As has previously been described,[19] the
level of sulforaphane in the urine reﬂects the consumption of
glucoraphanin containing vegetables within the previous 24 h, as
opposed to being a longer term marker of chronic consumption.
In contrast to sulforaphane and other isothiocyanates, SMCSO
and its derivatives accumulate and are excreted over a longer
period of time andmay provide a better biomarker of cruciferous
vegetable consumption, as has previously been suggested,[33] but
would also reﬂect consumption of alliaceous vegetables.
A previous study has reported that an oral gavage of 5 µmoles
(110 µmoles kg–1 body mass) of sulforaphane in mice resulted
in a transient presence of sulforaphane in prostate of between 50
and 100 pmoles after 6 h.[34] If we assume a 8% conversion of glu-
coraphanin to sulforaphane,[19] the human dose equivalent of glu-
coraphanin would be 8.8 mmoles or 32 portions of broccoli soup
based upon the US Food and Drug Administration algorithm for
calculating human dose equivalents from mouse studies.[35]
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Figure 8. a) SMCSO in plasma and b) in urine following consumption of single portion of broccoli soup at time 0. Points represent mean ± SD.
Table 2. Pharmacokinetic parameters of glucoraphanin, sulforaphane +
metabolites and SMCSO following consumption of 300 mL portion of
broccoli soup. Data for glucoraphanin and sulforaphane has previously
been published by Sivapalan et al.[19]
Glucoraphanin Sulforaphane and
metabolitesa)
SMCSO
Amount consumed
[µmoles]
280 ± 8.8 0 1513 ± 36.8
Plasma
AUC [µmol h L−1] 0.15 ± 0.08 4.92 ± 3.77 195.34 ± 40.42
Cmax [µmol L
−1] 0.03 ± 0.01 0.37 ± 0.26 28.03 ± 5.39
Tmax [h] 2.23 ± 0.09 9.20 ± 5.27 1.70 ± 0.35
C24h [µmol L
−1] <0.01 0.07 ± 0.06 4.66 ± 1.52
Urine
Total excreted in 24 h
[µmoles]
1.44 ± 0.66 23.14 ± 16.17 104.71 ± 46.16
Percentage excreted
after 24 h
0.51 ± 0.24 8.26 ± 5.78b) 6.92 ± 2.33
a)Sum of sulforaphane, sulforaphane-N-acetyl cysteine; sulforaphane-glutathione;
sulforaphane-cysteine; sulforaphane-cystine-glycine. b)As a percentage of gluco-
raphanin
In contrast, to the lack of sulforaphane, we found SMCSO to
be present in the prostate and peri-prostatic tissue of all partici-
pants, and at signiﬁcantly greater levels in the supplementation
arm than the non-supplementation arm (Figure 4a). SMCSO also
occurred in urine and were correlated with that in prostate tis-
sue (Figure 4b). The presence of SMCSO in both prostate and
adipose tissues of all volunteers (control and supplemented) was
unexpected. It is likely that it is of dietary origin as there are no
known routes by whichmammals can synthesize SMCSO.[9] Fur-
thermore, we found SMCSO in prostate tissue of men who had
not been part of a dietary study (Figure 7).
Through the analyses of plasma and urine from volunteers
who consumed a single portion of the broccoli soup, we found
un-metabolized SMCSO occurring in plasma with Cmax 1.5 h af-
ter consumption (Figure 6) suggesting rapid absorption in the
upper GI tract and recovered about 6% of ingested SMCSO as
un-metabolized SMCSO in urine after 24 h. The plasma concen-
tration of SMCSO was about 1000-fold higher than that of gluco-
raphanin or sulforaphane (Table 2).
Previously, there has been only a single study of the
metabolism of SMCSO in humans. Waring and colleagues de-
scribe the feeding of 35S-labeled SMCSO to human volunteers,
Figure 9. a) The concentration of SMCSO and glucosinolates in sam-
ples of cruciferous vegetables. Each bar represents level in pooled sample
of vegetables purchased from retail outlet. The precise cultivars are un-
known. b) Mean ± SD of three samples of leek, garlic, onion, and broccoli
purchased from retail outlet. The cultivars are unknown.
and the recovery of 96% of the label in urine after 14 days,
of which 40% was inorganic sulfate, indicating almost com-
plete absorption of SMCSO (and/or its colonic microbiological
derivatives).[18] How SMCSO was metabolized is unknown, but
it is likely that it was due to initial cysteine-S-conjugate 𝛽 lyase
activity by gut microbiome, as opposed to mammalian enzyme
activity. Together with the study of Waring and colleagues,[18] this
suggests that about 90% of SMCSO that is consumed is metabo-
lized in vivo.
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The pharmacokinetics of glucoraphanin and sulforaphane
contrast with that of SMCSO. Very little of ingested gluco-
raphanin is absorbed intact. Between 2% and 15% is recovered
in urine as sulforaphane and associated thiol conjugates after
24 h, with little or no subsequent excretion.[19] It is assumed
that the unaccounted glucoraphanin is voided with feces. In
contrast, the majority (97%) of SMCSO is absorbed, either as un-
metabolized SMCSO or as unknown derivatives, and excretion
of SMCSO (and its derivatives) occurs over several days.[18] The
paucity of studies on human metabolism and pharmacokinetics
of SMCSO hinders the interpretation of the current study. It
was apparent that there was considerable variation in the levels
of SMCSO in prostate and peri-prostatic adipose tissues within
both arms of the experimental study and within tissue obtained
from men not on the study. It is conceivable that this is due
to diﬀerent dietary habits of the tissue donors with respect of
consumption of cruciferous and alliaceous vegetables. Further
more detailed and longer-term dietary intervention studies are
required to explore the basis to this observed variation in SMCSO
content of human tissues.
The major interest in the metabolism of SMCSO has been as
the causal agent of hemolytic anemia in cattle or sheep. When
fed cruciferous fodder crops SMCSO is cleaved within the rumen
due to microbial cysteine-S-conjugate 𝛽 lyase activity to gener-
ate the highly reactive methanesulfenic acid that reacts with it-
self to produce an array of products (Figure 1), including MMTS,
dimethyl disuﬁde, and dimethyl trisulﬁde.[9,12] Within the blood,
these products are thought to induce oxidative stress through de-
pletion of reduced glutathione leading, among other metabolic
eﬀects, to Heinze body formation and hemolysis,[36] although
SMCSO has also been speculated to have a positive eﬀect on hu-
man health.[36] Subsequent studies should seek to quantify SM-
CSO catabolic products in the circulation and their accumula-
tion in tissues. This will require a greater understanding of the
catabolism of SMCSO and development of analytical methods.
Several SMCSO catabolic products, such as sulphate, may be
similar or identical to those generated by endogenous human
metabolism.
The presence of un-metabolized SMCSO in prostate tissue
may result fromdelivery from the plasma or urinary reﬂux.While
we have demonstrated the presence of SMCSO in prostate tissue,
it is not clear whether it would have any metabolic activity itself,
or whether any activity would be of a consequence of its degrada-
tion to biologically active derivatives. It may be noteworthy that
there is increasing evidence for a microbiological community as-
sociated both with the urinary tract and the prostate itself that
may metabolise SMCSO to its active derivatives.[37–39]
Despite the occurrence of SMCSO at higher concentrations
than glucosinolates in Brassica vegetables (Figure 9a), this
compound has received little attentions regarding its potential
contribution to the health beneﬁts attributed to cruciferous
vegetable consumption. This may be due to the complexities of
its catabolism and distinguishing its metabolites from those of
endogenous human metabolism. SMCSO also occurs in allia-
ceous vegetables such as onions and garlic (Figure 9b), along
with additional S-alk(en)yl cysteine sulfoxides.[40] Consumption
of Allium has also been associated with reduction in prostate
cancer,[41] which may be mediated by these metabolites and their
derivatives. It is likely that S-alk(en)yl cysteine sulfoxides such
as alliin from garlic may also accumulate in tissues following
consumption in a similar manner to SMCSO.
This study highlights the potential role of SMCSO in mediat-
ing the putative eﬀects of diets rich in cruciferous and alliaceous
vegetable consumption in prevention of aggressive prostate can-
cer, and possibly other health beneﬁts. In contrast to glucosino-
lates, almost 100%of SMCSO appears to be absorbed from theGI
tract with the majority being metabolised probably by the gut mi-
crobiome to biologically active derivatives. Un-metabolized SM-
CSO is found in plasma and appears to accumulate in prostate.
Further studies are required to determine if this is of biologi-
cal importance. The relative importance, if any, of sulforaphane
and other glucosinolate derivatives, and SMCSO and its catabolic
products to the health beneﬁts of diets rich in cruciferous vegeta-
bles requires further investigation. Future studies need to focus
on gaining a greater understanding of the microbial and human
metabolism of SMCSO, the analyses of SMCSO catabolic prod-
ucts in the circulation and their accumulation in peripheral tis-
sues, and the biological activity of SMCSO and its catabolic prod-
ucts.
Finally, it has been reported that the human prostate does have
a commensal bacterial community.[37,42] It is therefore possible
that SMCSO accumulates in prostate tissue, and then is catabo-
lized by a resident microbial population to bioactive components
that may inhibit the proliferation of cancerous cell lines.
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